Item 9 Labs Corp.

Equities

INLB

US46564C2035

Healthcare Facilities & Services

Market Closed - OTC Markets Other stock markets 01:43:11 2024-05-21 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	-94.74%

2023	Item 9 Labs Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	CI
2023	Douglas Bowden Resigned as Chairman of the Board of Directors of Item 9 Labs Corp, Effective July 18, 2023	CI

Item 9 Labs Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022

May 16, 2022 at 04:16 pm EDT

Item 9 Labs Corp. reported earnings results for the second quarter and six months ended March 31, 2022. For the second quarter, the company reported sales was USD 6.64 million compared to USD 6.11 million a year ago. Net loss was USD 3.88 million compared to net income of USD 0.04902 million a year ago. Basic loss per share from continuing operations was USD 0.04. Diluted loss per share from continuing operations was USD 0.04.
For the six months, sales was USD 12.82 million compared to USD 9.15 million a year ago. Net loss was USD 7.22 million compared to USD 1.03 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.02 a year ago. Diluted loss per share from continuing operations was USD 0.08 compared to USD 0.02 a year ago.

Latest news about Item 9 Labs Corp.

Item 9 Labs Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-21	CI
Douglas Bowden Resigned as Chairman of the Board of Directors of Item 9 Labs Corp, Effective July 18, 2023	23-07-20	CI
Douglas Bowden Resign as Interim CEO of Item 9 Labs Corp	23-07-20	CI
Item 9 Labs Corp. Announces Resignation of Shane Evans as A Member of the Board of Directors	23-06-27	CI
Item 9 Labs Corp. cancelled the acquisition of Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc.	23-05-24	CI
Item 9 Labs Corp. Announces Management Changes	23-05-23	CI
Item 9 Labs Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-22	CI
Item 9 Labs Corp. Announces Resignation of Michael Weinberger as Member of the Board of Directors	23-05-22	CI
Item 9 Labs Corp. Announces CEO Changes	23-05-22	CI
Item 9 Labs Corp. Announces the Resignation of Lawrence X. Taylor as Board of Director	23-05-12	CI
Item 9 Labs Releases Latest Limited Edition One-Gram Rosin-Infused Pre-Rolls	23-05-10	CI
Item 9 Labs Corp. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-14	CI
Item 9 Labs Corp. Reports Earnings Results for the Full Year Ended September 30, 2022	23-01-13	CI
Item 9 Labs Corp. Auditor Raises 'Going Concern' Doubt	23-01-12	CI
Item 9 Labs Corp. Announces Management Promotions	22-12-08	CI
Item 9 Labs Corp. Announces Resignation of Andrew Bowden as Director	22-11-30	CI
Item 9 Labs Corp. Announce Chief Executive Officer Changes	22-11-30	CI
Item 9 Labs Corp. announced that it expects to receive $25 million in funding from ClearThink Capital Partners, LLC	22-09-07	CI
Item 9 Labs Corp. Accelerates Growth of Unity Rd. Dispensary Franchise	22-08-18	CI
Earnings Flash (INLB) ITEM 9 LABS Reports Q3 Revenue $4.9M	22-08-16	MT
Item 9 Labs Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-15	CI
Item 9 Labs Corp. Nears Completion of Cannabis Cultivation and Lab Facility in Pahrump, Nevada	22-06-23	CI
Item 9 Labs Chief Strategy Officer Jeffrey Rassas Resigns	22-06-03	MT
Item 9 Labs Corp Announces Resignation of Jeffrey Rassas as the Chief Strategy Officer	22-06-03	CI
Item 9 Labs Corp. signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million.	22-05-23	CI

Chart Item 9 Labs Corp.

Duration

Period

More charts

Company Profile

Item 9 Labs Corp. is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The Company also offers a dispensary franchise model through the national Unity Rd. retail brand. The Company offers approximately 75 active cannabis strains and more than 150 differentiated cannabis vaporizer (vape) products, as well as premium concentrates and Orion vape technologies. The Company's Item 9 Labs brand specializes in select products and user experience across several cannabis categories. The Company operates through two segments: Cultivation and Franchising. Its product lines include Item 9 Labs Flower, Item 9 Labs Concentrates, and Orion 710.

Sector

Healthcare Facilities & Services

More about the company

	1st Jan change	Capi.
ITEM 9 LABS CORP.	-94.74%	70.19K
CRUCIAL INNOVATIONS CORP.	-.--%	339M
AYR WELLNESS INC.	+48.56%	291M
ASCEND WELLNESS HOLDINGS, INC.	+25.77%	260M
ORGANIGRAM HOLDINGS INC.	+51.16%	197M
INTERCURE LTD.	+155.24%	150M
JUSHI HOLDINGS INC.	+48.02%	134M
IANTHUS CAPITAL HOLDINGS, INC.	-42.86%	96.96M
THE CANNABIST COMPANY HOLDINGS INC.	-40.82%	121M
4FRONT VENTURES CORP.	+7.69%	93.89M

Medical Farming

Item 9 Labs Corp.

Equities

INLB

US46564C2035

Healthcare Facilities & Services

Item 9 Labs Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022

Latest news about Item 9 Labs Corp.

Chart Item 9 Labs Corp.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Medical Farming